Corporate Greed Case Study: Edwards Lifesciences and Its Impact on Heart Patients
A Lifeline in Jeopardy
For the eight million Americans over 50 suffering from aortic regurgitation (AR), the future of their treatment hangs in the balance.
This serious and often fatal heart condition, where a leaky valve causes blood to flow backward into the heart, can lead to heart failure and sudden death. For many, particularly the elderly and frail, the only current treatment—open-heart surgery—is too risky.
A revolutionary, less invasive technology known as transcatheter aortic valve replacement (TAVR) offers a lifeline. Yet, this beacon of hope is now threatened by a corporate strategy designed to consolidate power and eliminate competition, potentially leaving countless patients with fewer, slower, and less innovative options.
At the heart of this story are two companies, Edwards Lifesciences and JenaValve, the only two firms with TAVR devices for AR in clinical trials in the United States. Edwards’ proposed acquisition of JenaValve threatens to merge these two pioneers into one, creating a monopoly and extinguishing the competitive spark that drives life-saving innovation.
The Corporate Playbook: How the Harm Was Done
The strategy employed by Edwards Lifesciences, a global giant in medical devices, was a bold and calculated gambit to corner the emerging market for TAVR-AR technology. The company didn’t just target one competitor; it moved to acquire both of the leading innovators in the space.
Two of them!!
First, Edwards acquired JC Medical, the developer of the “J-Valve” TAVR-AR device. Then, it executed an agreement to buy its only other rival, JenaValve, the creator of the “Trilogy” system.
This two-pronged acquisition strategy would effectively transform a burgeoning duopoly into a monopoly overnight. The Federal Trade Commission (FTC) alleges this move would eliminate the “vigorous head-to-head competition” between the companies.
This competition is the engine that has pushed both firms to accelerate clinical trials, improve their devices, and expand treatment access to more patients. By bringing both the J-Valve and the Trilogy valve under one roof, Edwards would have total control, with little external pressure to continue innovating at the same pace.
A Cascade of Consequences: The Real-World Impact
Public Health & Safety at Risk
The most immediate and devastating consequence of this merger would be a slowdown in medical innovation. Competition between Edwards/JC Medical and JenaValve has forced both to be better, faster, and more effective. For instance, competitive pressure from JC Medical spurred JenaValve to launch a new, larger clinical trial aimed at making its Trilogy valve available to even more patients. This healthy rivalry directly benefits patients by expanding access and improving technology.
With a monopoly, Edwards would have little incentive to maintain this pace. Internal documents reveal a concerning future: if the acquisition proceeds, JenaValve anticipates a significant delay or reduction in its projects.
Edwards itself has indicated it would likely de-prioritize or even abandon one of the two valves, as there is little business reason to maintain two separate devices that treat the same condition.
This would rob patients and doctors of choice and could shelve a potentially superior technology simply for corporate convenience. The vibrant competition that pushes for better clinical outcomes, such as developing devices that reduce the need for a pacemaker post-surgery, would be extinguished.
The Erosion of Patient Hope
For those diagnosed with severe AR, the prospect of a less invasive treatment is life-changing. One in four people with this condition will die within a year if left untreated. The TAVR-AR devices from JenaValve and JC Medical represent the only viable alternative for high-risk patients who cannot undergo open-heart surgery.
The proposed merger threatens to delay access to these treatments and diminish the quality of future innovations. The head-to-head competition for placement in clinical trial sites at major research institutions and for the best medical specialists would cease, further stagnating the field. Patients will suffer if the ongoing competition, which drives the rapid advancement of this critical technology, is halted.
A System Designed for This: Profit, Deregulation, and Power
This is a direct consequence of our current neoliberal political and economic system that prioritizes profit maximization and market consolidation over public welfare. In the landscape of neoliberal capitalism, especially within the healthcare sector, corporations are incentivized to eliminate competition as a primary business strategy. Acquiring a competitor is often seen as a more reliable path to profit than out-innovating them.
Edwards Lifesciences, already a dominant player in the multi-billion dollar market for other TAVR devices, is following a familiar playbook. By seeking to acquire the only two companies with viable TAVR-AR devices in late-stage development, Edwards aims to preemptively capture a market before it even fully forms.
This strategy ensures market dominance and pricing power, but it comes at the expense of the very innovation that the system purports to champion. The FTC’s intervention highlights the failure of the market to regulate itself and the necessity of government oversight to protect the public from the predictable consequences of unchecked corporate power.
Dodging Accountability: How the Powerful Evade Justice
The FTC’s complaint is a preventative measure, an attempt to stop the harm before it becomes irreversible. For months, the Commission staff repeatedly offered Edwards a path to resolve the antitrust concerns: divest JC Medical to clear the way for the JenaValve acquisition.
This would have preserved a competitive market with two distinct players. However, Edwards repeatedly rejected this compromise, signaling its ultimate goal was not just to acquire JenaValve’s technology, but to control the entire market.
This refusal to divest demonstrates a corporate mentality that sees regulatory hurdles not as safeguards for the public good, but as obstacles to be overcome in the pursuit of total market control. Without government intervention, the merger would likely proceed, and any subsequent harm—such as slowed innovation or higher prices—would be incredibly difficult to undo.
The legal action is a crucial check on a system that often allows corporations to prioritize shareholder returns over patient lives, with accountability often coming too late, if at all.
Reclaiming Power: Pathways to Real Change
The FTC’s legal challenge in this case is a vital step toward ensuring that medical innovation serves patients, not just corporate balance sheets. It underscores the critical role of robust antitrust enforcement in the healthcare sector, where the stakes are life and death. To prevent similar situations in the future, systemic reforms are necessary. This includes strengthening regulatory oversight of mergers and acquisitions in critical industries like medical devices, empowering agencies like the FTC with greater resources and authority.
Furthermore, there needs to be a broader societal conversation about the purpose of healthcare innovation. Is it merely a tool for generating profit, or is it a public good that should be nurtured and protected? True change requires shifting the focus from a system that rewards the elimination of competition to one that fosters a diverse and competitive landscape dedicated to advancing public health.
Conclusion: A Story of a System, Not an Exception
The planned acquisition of JenaValve by Edwards Lifesciences is more than a simple business transaction; it is a ghastly illustration of a systemic problem. It reveals how our modern economy can incentivize a single powerful entity to swallow up its nascent rivals, thereby choking off the very competition that drives progress and saves lives.
This is emblematic a much larger crisis where the relentless pursuit of monopoly power threatens the well-being of us all.
All factual claims in this article were derived from the public complaint filed by the U.S. Federal Trade Commission in the matter of Edwards Lifesciences Corp. and JenaValve Technology, Inc., Docket No. 9442, dated August 6, 2025.
You can read about this antitrust blocking by visiting the FTC’s website: https://www.ftc.gov/news-events/news/press-releases/2025/08/ftc-challenges-anticompetitive-medical-device-deal
Full disclosure, but Edward Lifesciences did also respond to the FTC’s blocking. You can read about that on their website if you want to see some corporate PR in action: https://ir.edwards.com/news/news-details/2025/Edwards-Lifesciences-Comments-on-FTCs-Action-to-Block-Proposed-Acquisition-of-JenaValve/default.aspx
💡 Explore Corporate Misconduct by Category
Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.
- 💀 Product Safety Violations — When companies risk lives for profit.
- 🌿 Environmental Violations — Pollution, ecological collapse, and unchecked greed.
- 💼 Labor Exploitation — Wage theft, worker abuse, and unsafe conditions.
- 🛡️ Data Breaches & Privacy Abuses — Misuse and mishandling of personal information.
- 💵 Financial Fraud & Corruption — Lies, scams, and executive impunity.
